Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortization of Deferred ChargesAsset Writedowns and ImpairmentAsset Writedowns and ImpairmentCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in CashChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesGains from Sales and DivestituresGains from Sales and DivestituresNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Neuroone Medical Technologies (NMTC) Change in Accured Expenses (2016 - 2026)

Neuroone Medical Technologies filings provide 12 years of Change in Accured Expenses readings, the most recent being $31133.0 for Q1 2026.

  • On a quarterly basis, Change in Accured Expenses fell 4.35% to $31133.0 in Q1 2026 year-over-year; TTM through Mar 2026 was -$211941.0, a 3841.9% decrease, with the full-year FY2025 number at -$54442.0, down 435.77% from a year prior.
  • Change in Accured Expenses hit $31133.0 in Q1 2026 for Neuroone Medical Technologies, up from -$619376.0 in the prior quarter.
  • In the past five years, Change in Accured Expenses ranged from a high of $1.7 million in Q3 2022 to a low of -$1.4 million in Q1 2023.
  • Median Change in Accured Expenses over the past 5 years was $73839.0 (2025), compared with a mean of -$5853.6.
  • Biggest five-year swings in Change in Accured Expenses: surged 1227.97% in 2022 and later crashed 7447.94% in 2023.
  • Neuroone Medical Technologies' Change in Accured Expenses stood at -$306125.0 in 2022, then plummeted by 69.4% to -$518584.0 in 2023, then increased by 10.66% to -$463292.0 in 2024, then crashed by 33.69% to -$619376.0 in 2025, then soared by 105.03% to $31133.0 in 2026.
  • The last three reported values for Change in Accured Expenses were $31133.0 (Q1 2026), -$619376.0 (Q4 2025), and $302463.0 (Q3 2025) per Business Quant data.